Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
The Lancet Regional Health - Southeast Asia · 2026-04 · 47 · 100743
DOI: 10.1016/j.lansea.2026.100743 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Regional Health - Southeast Asia, 2026-04. Verfasst von Praveen Kumar Marimuthu und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Christian Medical College Vellore, India. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Christian Medical College, Vellore.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Non-surgical management of oral cavity squamous cell carcinoma (OSCC) has poorer outcomes compared to surgery. In borderline resectable tumors, historical neoadjuvant chemotherapy achieves surgical conversion in only about 40%. Combining low-dose immunotherapy and oral metronomic therapy (OMT) with chemotherapy may enhance resection rate and survival.
Methods
Between April 2023 and April 2024, patients deemed 'borderline resectable' OSCC based on predefined criteria by a multidisciplinary tumor board were prospectively offered this Phase II single-arm interventional trial setting. Patients received two 21-day cycles of carboplatin, nab-paclitaxel, low-dose nivolumab, and six weeks of erlotinib, methotrexate, celecoxib, with additional cycle(s) if needed. Primary endpoint was R0 resection rate. Secondary endpoints were objective response rate, pathologic response, safety, event-free survival (EFS), and overall survival (OS). Immune biomarkers and Volumetric assessment were exploratory endpoints. The trial was prospectively registered in the Clinical Trial Registry of India (CTRI/2023/04/051617).
Findings
Of 34 patients, all except one completed planned neoadjuvant therapy. After 2 cycles, 22 (66·6%) had partial response and 11 had stable disease; none progressed. Twenty six underwent surgery; 25 achieved R0 resection (25/33-75·7% conversion). Four of seven remaining patients received additional cycle(s); three subsequently achieved R0 resection. Overall conversion rate was 90·3% (28/31) excluding 2 patients who refused further treatment. Major pathological response occurred in 12 patients (41·4%), including four with pathological complete response. Grade ≥3 toxicities occurred in 5 of 34 patients (14·7%), with no treatment-related deaths. One patient had grade 4 diarrhea with grade 4 acute kidney injury.
Interpretation
The NeoLOCUS regimen offers an affordable, outpatient chemo-immunotherapy approach that improves surgical conversion and pathological response in borderline resectable OSCC. Funding: Fluid Research Grant- Christian Medical College, Vellore, India.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Christian Medical College Vellore, India.
- Department of General Pathology, Christian Medical College Vellore, India.
- Department of Radiology, Christian Medical College Vellore, India.
- Department of Head and Neck Surgery, Christian Medical College Vellore, India.
- Department of Radiation Oncology, Christian Medical College Vellore, India.
- Department of Biostatistics, Christian Medical College Vellore, India.
Förderung
- Christian Medical College, Vellore
Zitieren
APA
Marimuthu, P. K., Renukaradhya, C., Sahu, S., John, A. O., Tirkey, A. J., Sasidharan, B. K., Vidya, K., Riju, J., Agrawal, M., Thomas, M., Wilson, J. V., Joel, A., Sidhique, S. K., Georgy, J. T., Thumaty, D. B., Philip, D. S. J., Harikrishna, K., Subbarao, A. K., Mathew, M., …, & Singh, A. (2026). Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial. The Lancet Regional Health - Southeast Asia, 47, 100743. https://doi.org/10.1016/j.lansea.2026.100743
Vancouver
Marimuthu PK, Renukaradhya C, Sahu S, John AO, Tirkey AJ, Sasidharan BK, et al. Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial. The Lancet Regional Health - Southeast Asia. 2026;47:100743. doi:10.1016/j.lansea.2026.100743
BibTeX
@article{Marimuthu2026,
author = {Marimuthu, Praveen Kumar and Renukaradhya, Chitra and Sahu, Shalini and John, Ajoy Oommen and Tirkey, Amit Jiwan and Sasidharan, Balu Krishna and Vidya, Konduru and Riju, Jeyashanth and Agrawal, Mansi and Thomas, Meera and Wilson, Jino Victor and Joel, Anjana and Sidhique, Sharief K and Georgy, Josh Thomas and Thumaty, Divya Bala and Philip, Deepa Susan Joy and Harikrishna, Kovilapu and Subbarao, Anil Kumar and Mathew, Manu and Pavamani, Simon Pradeep and Michael, Rajiv C and Isiah, Rajesh and Rani, Jansi and Singh, Ashish},
title = {Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial},
journal = {The Lancet Regional Health - Southeast Asia},
year = {2026},
volume = {47},
pages = {100743},
doi = {10.1016/j.lansea.2026.100743}
}
EUVIMED